Nurix therapeutics announces extension of strategic collaboration with sanofi to develop novel targeted protein degraders of stat6

Goal is to develop an oral stat6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation

NRIX Ratings Summary

NRIX Quant Ranking